Clinical trials: Prognostic Cancer Model
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
NSCLC Stage IIIA/B, NSCLC Stage II
Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective
This research focuses on exploring biomarkers for the application of PD - 1/PD - L1 immune checkpoint inhibitors in the perioperative immunotherapy of lung cancer.
- Trial name
- NCT06856798
- Volunteers
- 120 people
- Sponsor
- Ziming Li
Neoplasms Pancreatic
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to…
- Trial name
- NCT05547074
- Testing
- pancreatic cancer surgery
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Zhejiang University
Prognostic Cancer Model, Chemotherapy
Colorectal Cancer Dataset in Xijing Hospital From 2011
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized…
- Conditions
- Prognostic Cancer Model, Chemotherapy, Nutrition Related Cancer
- Trial name
- NCT06308354
- Where
- China
- Volunteers
- 40,000 people
- Sponsor
- Xijing Hospital
Genomic Instability, Prognostic Cancer Model
Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases
A retrospective cohort of 286 patients with synchronous CRLM underwent conversion therapies based on next-generation sequencing (NGS) results.
- Trial name
- NCT06477718
- Volunteers
- 286 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Oncology
Assessing Perceptions of ML Explanations by Medical Oncologists
The objective of this proposal is to conduct a vignette-based survey among practicing oncology clinicians who treat non-small cell lung cancer to assess the trustworthiness of explainable predictions from a neurosymbolic AI vs.
- Trial name
- NCT06699615
- Testing
- Once time de-identified Qualtrics survey
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03939481
- Testing
- Chemotherapy, Functional Assessment, Questionnaire Administration
- Where
- 169 sites in United States, Chile and 2 more
- Volunteers
- 1,336 people
- Sponsor
- SWOG Cancer Research Network
AL Amyloidosis (AL), Cardiac Amyloidosis
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
1. Goal of the Study: The goal of this prospective observational study is to develop and validate a novel, non-invasive method for predicting the prognosis of patients with light-chain cardiac amyloidosis (AL-CA).
- Trial name
- AL-CA (NCT07103863)
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Anzhen Hospital
Melanoma
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy
This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.
- Trial name
- NCT03438279
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Cancer of Head and Neck
Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide)
The purpose of this study is to determine new multiscale signatures for the prediction of head and neck cancer (HNC) patients disease outcome, in particular for advanced stage (stage III, IV) human papillomavirus (HPV) negative…
- Trial name
- BD2Decide (NCT02832102)
- Testing
- Standard treatment of SCCHN patients
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 1,450 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV
Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma
The purpose of this research study is to investigate the relationship between vascular habitats and treatment response AND to investigate the potential utility of dynamic contrast enhanced (DCE)-MRI derived parameters in…
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OPSCC (NCT07797738)
- Testing
- MRI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lymphoma, Large B-Cell, Diffuse
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression
- Trial name
- NCT02928861
- Testing
- 18F-FDG PET/CT
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Predictive Cancer Model, Localized Prostate Carcinoma
Generation and Validation of Predictive Models for Localized Prostate Cancer Treated With External Radiotherapy.
The generation of predictive models in radiotherapy has seen a significant increase. In 2017, Raymond published the largest systematic review of predictive prognostic models for biochemical relapse (BR), metastasis-free survival…
- Trial name
- NCT06092918
- Testing
- EXTERNAL RADIOTHERAPY
- Volunteers
- 700 people
- Sponsor
- Consorci Sanitari de Terrassa
Head and Neck Cancer
Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology
Despite uniform histopathological definition the response of locally advanced squamous cell carcinomas of the head and neck (HNSCC) to ionizing radiation differs greatly with locoregional recurrences burdening this patient…
- Trial name
- NCT01829646
- Testing
- functional MRI, Hypoxia gene expression profile., Functional MRI before start of treatment.
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC)
Validation of RCC Predicting Model With Emulated-target Trial
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Tumor Thrombus, Prognosis
- Trial name
- RCCETT (NCT07117227)
- Testing
- Model-guided adjuvant treatment, No adjuvant treatment
- Where
- China
- Volunteers
- 4,700 people
- Sponsor
- Peking University Third Hospital
Predictive Cancer Model, Pathologic Complete Response
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing…
- Trial name
- NCT06364371
- Testing
- Medical examination
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cervical Cancer, Radiotherapy
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.
- Conditions
- Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model
- Trial name
- NCT06101966
- Testing
- external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fujian Cancer Hospital
Bladder Cancer
Study on the Staging and Prognosis Model of Bladder Cancer
Firstly, we retrospectively gathered the patient information who compliant with the criteria from 2012 to 2023, encompassing basic information, clinical information, along with MRI images, blood/urine samples, and tissue samples…
- Trial name
- 2024-SR-386 (NCT06565923)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Soft-tissue Sarcoma, Predictive Cancer Model
The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patients
The goal of this clinical trial is to assess the (cost-)effectiveness of a personalised risk assessment tool (PERSARC) to increase patients' knowledge about risks and benefits of treatment options and to reduce decisional…
- Trial name
- VALUE_PERSARC (NCT05741944)
- Testing
- Care with the use of PERSARC, standard care
- Where
- 7 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- Leiden University Medical Center
Predictive Cancer Model, Hepatic Metastasis
A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery
A previous study of investigators established a risk scoring model for occurrence of postoperative hepatic metastases in patients who underwent curative gastrectomy directly without neoadjuvant therapy.
- Conditions
- Predictive Cancer Model, Hepatic Metastasis, Gastric Cancer
- Trial name
- NCT06023966
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital